Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fuad Mirzayev

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Clinics in Chest Medicine|November 17, 2019
Tuberculosis Supranational Reference Laboratories: A Global ApproachChristopher Gilpin, Fuad Mirzayev
Drug Design, Development and Therapy|July 8, 2021
Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to DateStephani L Stancil, Fuad Mirzayev, Susan M Abdel-Rahman
The European Respiratory Journal|March 7, 2020
WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidenceDennis Falzon, Holger J Schünemann, Matteo Zignol, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 17, 2021
Situational analysis of 10 countries with a high burden of drug-resistant tuberculosis 2 years post-UNHLM declaration: progress and setbacks in a changing landscapeIgnacio Monedero-Recuero, Medea Gegia, Douglas Fraser Wares, et al.
The European Respiratory Journal|July 1, 2022
Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globallyTiziana Masini, Avinash Kanchar, Fuad Mirzayev, et al.
The European Respiratory Journal|March 24, 2018
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosisChristine M Halleux, Dennis Falzon, Corinne Merle, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|April 28, 2017
Mitigation of Discordant Rifampicin-Susceptibility Results Obtained by Xpert Mycobacterium tuberculosis/Rifampicin and Mycobacterium Growth Indicator TubeElmira Gurbanova, Rafail Mehdiyev, Kai Blondal, et al.
The European Respiratory Journal|November 27, 2020
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 updateFuad Mirzayev, Kerri Viney, Nguyen Nhat Linh, et al.
PLOS Global Public Health|March 24, 2023
Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosisAastha Gupta, Sandeep Juneja, Suvanand Sahu, et al.
The Lancet. Global Health|May 18, 2024
Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysisTheresa S Ryckman, Samuel G Schumacher, Christian Lienhardt, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Clinics in Chest Medicine|November 17, 2019
Tuberculosis Supranational Reference Laboratories: A Global ApproachChristopher Gilpin, Fuad Mirzayev
Drug Design, Development and Therapy|July 8, 2021
Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to DateStephani L Stancil, Fuad Mirzayev, Susan M Abdel-Rahman
The European Respiratory Journal|March 7, 2020
WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidenceDennis Falzon, Holger J Schünemann, Matteo Zignol, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 17, 2021
Situational analysis of 10 countries with a high burden of drug-resistant tuberculosis 2 years post-UNHLM declaration: progress and setbacks in a changing landscapeIgnacio Monedero-Recuero, Medea Gegia, Douglas Fraser Wares, et al.
The European Respiratory Journal|July 1, 2022
Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globallyTiziana Masini, Avinash Kanchar, Fuad Mirzayev, et al.
The European Respiratory Journal|March 24, 2018
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosisChristine M Halleux, Dennis Falzon, Corinne Merle, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|April 28, 2017
Mitigation of Discordant Rifampicin-Susceptibility Results Obtained by Xpert Mycobacterium tuberculosis/Rifampicin and Mycobacterium Growth Indicator TubeElmira Gurbanova, Rafail Mehdiyev, Kai Blondal, et al.
The European Respiratory Journal|November 27, 2020
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 updateFuad Mirzayev, Kerri Viney, Nguyen Nhat Linh, et al.
PLOS Global Public Health|March 24, 2023
Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosisAastha Gupta, Sandeep Juneja, Suvanand Sahu, et al.
The Lancet. Global Health|May 18, 2024
Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysisTheresa S Ryckman, Samuel G Schumacher, Christian Lienhardt, et al.
Pageof 3